Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D BioPharmaceuticals, AstraZeneca, Cambridge CB2 0AA, U.K.
Advanced Drug Delivery, Pharmaceutical Sciences, R&D BioPharmaceuticals, AstraZeneca, Macclesfield SK10 2NA, U.K.
Anal Chem. 2021 Mar 2;93(8):3742-3749. doi: 10.1021/acs.analchem.0c03908. Epub 2021 Feb 19.
Imaging mass cytometry (IMC) offers the opportunity to image metal- and heavy halogen-containing xenobiotics in a highly multiplexed experiment with other immunochemistry-based reagents to distinguish uptake into different tissue structures or cell types. However, in practice, many xenobiotics are not amenable to this analysis, as any compound which is not bound to the tissue matrix will delocalize during aqueous sample-processing steps required for IMC analysis. Here, we present a strategy to perform IMC experiments on a water-soluble polysarcosine-modified dendrimer drug-delivery system (S-Dends). This strategy involves two consecutive imaging acquisitions on the same tissue section using the same instrumental platform, an initial laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MSI) experiment followed by tissue staining and a standard IMC experiment. We demonstrated that settings can be found for the initial ablation step that leave sufficient residual tissue for subsequent antibody staining and visualization. This workflow results in lateral resolution for the S-Dends of 2 μm followed by imaging of metal-tagged antibodies at 1 μm.
成像质谱流式细胞术(IMC)提供了一个机会,可以在一个高度多重的实验中对含有金属和重卤素的外来化合物进行成像,同时使用其他基于免疫化学的试剂来区分它们进入不同组织结构或细胞类型的摄取情况。然而,在实践中,许多外来化合物并不适合这种分析,因为在 IMC 分析所需的水相样品处理步骤中,任何未与组织基质结合的化合物都会发生离域。在这里,我们提出了一种在水溶性聚肌氨酸修饰的树枝状大分子药物传递系统(S-Dends)上进行 IMC 实验的策略。该策略涉及在同一组织切片上使用相同的仪器平台进行两次连续的成像采集,首先是激光烧蚀电感耦合等离子体质谱(LA-ICP-MSI)实验,然后是组织染色和标准的 IMC 实验。我们证明,可以找到初始烧蚀步骤的设置,为后续的抗体染色和可视化留下足够的残留组织。该工作流程可使 S-Dends 的横向分辨率达到 2μm,然后以 1μm 的分辨率对金属标记的抗体进行成像。